IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy
Immunity · 2026-01 · 59 (1) · 177-194.e12
DOI: 10.1016/j.immuni.2025.10.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, 2026-01. Verfasst von Hua Jiang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; Departments of Molecular and Cellular Physiology a…. Hauptthemen laut MEDLINE: Interleukin-9, Janus Kinases, T-Lymphocytes, STAT Transcription Factors. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanfor…
- Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
- Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Medical Scientist Training Program, Stanford University School of Medicine, Stanford, CA 94143, USA; Stanford C…
- Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.
- Broad Stem Cell Research Center, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, CA 90095,…
- Department of Pathology & Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Broad Stem Cell Research Center, University of California, Los Angeles, Los Angeles, CA 90095, USA; Divis…
Förderung
- NCI NIH HHS
- NIH HHS
- NIAID NIH HHS
- NIGMS NIH HHS
- NIH National Cancer Institute
- National Institute of General Medical Sciences
- Damon Runyon Cancer Research Foundation
- Cancer Research Institute
Zitieren
APA
Jiang, H., Limsuwannarot, S., Kulhanek, K. R., Pal, A., Labiad, O., Rysavy, L. W., Wong, A., Su, L., Cavender, S., Soro, J., Testa, S., Ogana, H., Waghray, D., Tao, P., Jude, K. M., Seet, C. S., Crooks, G. M., Moding, E. J., Garcia, K. C., & Kalbasi, A. (2026). IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy. Immunity, 59(1), 177-194.e12. https://doi.org/10.1016/j.immuni.2025.10.024
Vancouver
Jiang H, Limsuwannarot S, Kulhanek KR, Pal A, Labiad O, Rysavy LW, et al. IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy. Immunity. 2026;59(1):177-194.e12. doi:10.1016/j.immuni.2025.10.024
BibTeX
@article{Jiang2026,
author = {Jiang, Hua and Limsuwannarot, Sam and Kulhanek, Kayla R and Pal, Aastha and Labiad, Ossama and Rysavy, Lea W and Wong, Ada and Su, Leon and Cavender, Sarah and Soro, Johnathon and Testa, Stefano and Ogana, Heather and Waghray, Deepa and Tao, Pingdong and Jude, Kevin M and Seet, Christopher S and Crooks, Gay M and Moding, Everett J and Garcia, K Christopher and Kalbasi, Anusha},
title = {IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy},
journal = {Immunity},
year = {2026},
volume = {59},
number = {1},
pages = {177--194.e12},
doi = {10.1016/j.immuni.2025.10.024}
}
EUVIMED